These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 31618685)

  • 1. LRRK2 inhibition prevents endolysosomal deficits seen in human Parkinson's disease.
    Rocha EM; De Miranda BR; Castro S; Drolet R; Hatcher NG; Yao L; Smith SM; Keeney MT; Di Maio R; Kofler J; Hastings TG; Greenamyre JT
    Neurobiol Dis; 2020 Feb; 134():104626. PubMed ID: 31618685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The industrial solvent trichloroethylene induces LRRK2 kinase activity and dopaminergic neurodegeneration in a rat model of Parkinson's disease.
    De Miranda BR; Castro SL; Rocha EM; Bodle CR; Johnson KE; Greenamyre JT
    Neurobiol Dis; 2021 Jun; 153():105312. PubMed ID: 33636387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the focal role of LRRK2 kinase in Parkinson's disease.
    Kumar S; Behl T; Sehgal A; Chigurupati S; Singh S; Mani V; Aldubayan M; Alhowail A; Kaur S; Bhatia S; Al-Harrasi A; Subramaniyan V; Fuloria S; Fuloria NK; Sekar M; Abdel Daim MM
    Environ Sci Pollut Res Int; 2022 May; 29(22):32368-32382. PubMed ID: 35147886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LRRK2 kinase inhibition protects against Parkinson's disease-associated environmental toxicants.
    Ilieva NM; Hoffman EK; Ghalib MA; Greenamyre JT; De Miranda BR
    Neurobiol Dis; 2024 Jun; 196():106522. PubMed ID: 38705492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.
    Sloan M; Alegre-Abarrategui J; Potgieter D; Kaufmann AK; Exley R; Deltheil T; Threlfell S; Connor-Robson N; Brimblecombe K; Wallings R; Cioroch M; Bannerman DM; Bolam JP; Magill PJ; Cragg SJ; Dodson PD; Wade-Martins R
    Hum Mol Genet; 2016 Mar; 25(5):951-63. PubMed ID: 26744332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical modeling of chronic inhibition of the Parkinson's disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo.
    Kluss JH; Mazza MC; Li Y; Manzoni C; Lewis PA; Cookson MR; Mamais A
    Mol Neurodegener; 2021 Mar; 16(1):17. PubMed ID: 33741046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LRRK2 and idiopathic Parkinson's disease.
    Rocha EM; Keeney MT; Di Maio R; De Miranda BR; Greenamyre JT
    Trends Neurosci; 2022 Mar; 45(3):224-236. PubMed ID: 34991886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons.
    Schapansky J; Khasnavis S; DeAndrade MP; Nardozzi JD; Falkson SR; Boyd JD; Sanderson JB; Bartels T; Melrose HL; LaVoie MJ
    Neurobiol Dis; 2018 Mar; 111():26-35. PubMed ID: 29246723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LRRK2 activation in idiopathic Parkinson's disease.
    Di Maio R; Hoffman EK; Rocha EM; Keeney MT; Sanders LH; De Miranda BR; Zharikov A; Van Laar A; Stepan AF; Lanz TA; Kofler JK; Burton EA; Alessi DR; Hastings TG; Greenamyre JT
    Sci Transl Med; 2018 Jul; 10(451):. PubMed ID: 30045977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel ethyl methanesulfonate (EMS)-induced null alleles of the Drosophila homolog of LRRK2 reveal a crucial role in endolysosomal functions and autophagy in vivo.
    Dodson MW; Leung LK; Lone M; Lizzio MA; Guo M
    Dis Model Mech; 2014 Dec; 7(12):1351-63. PubMed ID: 25288684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.
    Daher JP; Abdelmotilib HA; Hu X; Volpicelli-Daley LA; Moehle MS; Fraser KB; Needle E; Chen Y; Steyn SJ; Galatsis P; Hirst WD; West AB
    J Biol Chem; 2015 Aug; 290(32):19433-44. PubMed ID: 26078453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LRRK2 and the Endolysosomal System in Parkinson's Disease.
    Erb ML; Moore DJ
    J Parkinsons Dis; 2020; 10(4):1271-1291. PubMed ID: 33044192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-Dependent Dopaminergic Neurodegeneration and Impairment of the Autophagy-Lysosomal Pathway in LRRK-Deficient Mice.
    Giaime E; Tong Y; Wagner LK; Yuan Y; Huang G; Shen J
    Neuron; 2017 Nov; 96(4):796-807.e6. PubMed ID: 29056298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LRRK2 Kinase Inhibitor Rejuvenates Oxidative Stress-Induced Cellular Senescence in Neuronal Cells.
    Ho DH; Nam D; Seo MK; Park SW; Seol W; Son I
    Oxid Med Cell Longev; 2021; 2021():9969842. PubMed ID: 34306319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dietary Amino Acids Impact LRRK2-Induced Neurodegeneration in Parkinson's Disease Models.
    Chittoor-Vinod VG; Villalobos-Cantor S; Roshak H; Shea K; Abalde-Atristain L; Martin I
    J Neurosci; 2020 Aug; 40(32):6234-6249. PubMed ID: 32605938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The G2019S variant of leucine-rich repeat kinase 2 (LRRK2) alters endolysosomal trafficking by impairing the function of the GTPase RAB8A.
    Rivero-Ríos P; Romo-Lozano M; Madero-Pérez J; Thomas AP; Biosa A; Greggio E; Hilfiker S
    J Biol Chem; 2019 Mar; 294(13):4738-4758. PubMed ID: 30709905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
    Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
    Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling Parkinson's disease in LRRK2 mice: focus on synaptic dysfunction and the autophagy-lysosomal pathway.
    Albanese F; Domenicale C; Volta M; Morari M
    Biochem Soc Trans; 2022 Feb; 50(1):621-632. PubMed ID: 35225340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration.
    Tsika E; Kannan M; Foo CS; Dikeman D; Glauser L; Gellhaar S; Galter D; Knott GW; Dawson TM; Dawson VL; Moore DJ
    Neurobiol Dis; 2014 Nov; 71():345-58. PubMed ID: 25174890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LRRK2 Ablation Attenuates Αlpha-Synuclein-Induced Neuroinflammation Without Affecting Neurodegeneration or Neuropathology In Vivo.
    Van der Perren A; Cabezudo D; Gelders G; Peralta Ramos JM; Van den Haute C; Baekelandt V; Lobbestael E
    Neurotherapeutics; 2021 Apr; 18(2):949-961. PubMed ID: 33594532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.